According to filings with the U.S. Securities and Exchange Commission, Epitel has raised $26 Million in new Series B funding. The federal securities law requires the notice to be filed by companies that have sold securities without registration under the Securities Act of 1933 in an offering made under Rule 504 or 506 of Regulation D or Section 4(a)(5) of the Securities Act. A company must file this notice within 15 days after the first sale of securities in the offering. For this purpose, the date of first sale is the date on which the first investor is irrevocably contractually committed to invest. Each issuer of securities that sells its securities in reliance on an exemption provided in Regulation D or Section 4(a)(5) of the Securities Act of 1933 must file this notice containing the information requested with the U.S. Securities and Exchange Commission (SEC) and with the state(s) requiring it. If more than one issuer has sold its securities in the same transaction, all issuers should be identified in this filing with the SEC.

Investors in the company’s current round of funding include: Catalyst Health Ventures, Genoa Ventures

About Epitel
Epitel is a digital health company focused on modernizing brain health solutions by improving seizure monitoring and detection. Based on its website, the company develops a proprietary cloud-based wearable EEG sensor system that makes electroencephalography (EEG) readily deployable and accessible across diverse care settings. Epitels primary business centers on a wearable, wireless EEG monitoring platform designed to provide accessible, affordable, and reliable electrographic seizure detection, empowering clinicians with better data to guide treatment decisions. The companys first product, the REMI Remote EEG Monitoring System, is FDA cleared and enables remote EEG monitoring, extending medical grade brain monitoring beyond large tertiary hospitals into community and rural hospitals and potentially the home. Headquartered in Salt Lake City, Epitel positions itself as a leader in democratizing brain health monitoring through wearable sensors and AI enabled analytics that connect patients, caregivers, and physicians for improved epilepsy and neurological care.

To learn more, visit https://www.epitel.com/
Linkedin: https://www.linkedin.com/company/epitel-inc

Contact:
Steven Pacelli, Chief Executive Officer
https://www.linkedin.com/in/steven-pacelli-74210233a

SOURCE: http://www.intelligence360.io
Copyright (c) 2026 SI360 Inc. All rights reserved.